Sanofi 주식 가격. 1SAN - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

가격

106.20

매수가

102.00

매도가

110.00

거래량

124

106.28 일간 변동폭 106.78

85.14 52주 범위 110.40

market_cap

133.03B

전일 종가

106.10

개장가

106.56

최근 거래 시간

106.28

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

727

발행 주식

1,252,640,466

배당수익률

3.54%

주가수익률

23.93

주당순이익(EPS)

4.44

매출

46.11B

순이익

5.56B

섹터

Health & Allied Services,nec

산업

Pharmaceutical Preparations

웹사이트

www.sanofi.com

본부

Paris, Paris, Fra

설립됨

1994

Sanofi is listed in the Health & Allied Services sector of the 이탈리아 증권거래소 with ticker 1SAN. The last closing price for Sanofi was 106.10 €. Over the last year, Sanofi shares have traded in a share price range of 85.14 € to 110.40 €.

Sanofi currently has 1,252,640,466 shares in issue. The market capitalisation of Sanofi is 132.91 € billion. Sanofi has a price to earnings ratio (PE ratio) of 23.93.

Communiqué de presse : Présentation de dernière heure de données pivots positives sur le Dupixent dans le traitement de la pemphigoïde bulleuse à l’AAD

Communiqué de presse : Présentation de dernière heure de données pivots positives sur le Dupixent dans le traitement de la pemphigoïde bulleuse à...

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Dupixent late-breaking positive pivotal data in...

Press release: Sanofi successfully prices EUR 1.5 billion of bond issue

Press release: Sanofi successfully prices EUR 1.5 billion of bond issue Sanofi successfully prices EUR 1.5 billion of bond issue Paris, March 5...

Communiqué de presse : Sanofi place 1,5 milliard d’euros d’emprunts obligataires

Communiqué de presse : Sanofi place 1,5 milliard d’euros d’emprunts obligataires Sanofi place 1,5 milliard d’euros d’emprunts obligataires Paris...

Communiqué de presse : Sarclisa approuvé au Japon pour le traitement du myélome multiple nouvellement diagnostiqué

Communiqué de presse : Sarclisa approuvé au Japon pour le traitement du myélome multiple nouvellement diagnostiqué Sarclisa approuvé au Japon pour...

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Sarclisa approved in Japan for patients with newly...

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease ECCO 2025: new duvakitug...

Communiqué de presse : ECCO 2025 : de nouvelles données sur le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn

Communiqué de presse : ECCO 2025 : de nouvelles données sur le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le...

Press Release: Sanofi and CD&R sign Opella share purchase agreement

Press Release: Sanofi and CD&R sign Opella share purchase agreement Sanofi and CD&R sign Opella share purchase agreement Paris, February...

Communiqué de presse : Sanofi et CD&R annoncent la signature de l’accord d’achat des actions d’Opella

Communiqué de presse : Sanofi et CD&R annoncent la signature de l’accord d’achat des actions d’Opella Sanofi et CD&R annoncent la...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	1.6	1.52963671128	104.6	110.4	94.46	595	107.63175126	DE
4	1.8	1.72413793103	104.4	110.4	94.46	650	106.91416289	DE
12	15.56	17.1668137688	90.64	110.4	89.92	727	101.62138262	DE
26	2.52	2.43055555556	103.68	110.4	87.48	712	98.12780601	DE
52	17.04	19.1117092867	89.16	110.4	85.14	850	95.31154244	DE
156	17.24	19.3794964029	88.96	110.4	76.36	881	92.28897842	DE
260	35.37	49.9364675985	70.83	110.4	68	1392	88.05771124	DE

1SAN - Frequently Asked Questions (FAQ)

What is the current Sanofi share price?

The current share price of Sanofi is 106.20 €

How many Sanofi shares are in issue?

Sanofi has 1,252,640,466 shares in issue

What is the market cap of Sanofi?

The market capitalisation of Sanofi is EUR 132.91B

What is the 1 year trading range for Sanofi share price?

Sanofi has traded in the range of 85.14 € to 110.40 € during the past year

What is the PE ratio of Sanofi?

The price to earnings ratio of Sanofi is 23.93

What is the cash to sales ratio of Sanofi?

The cash to sales ratio of Sanofi is 2.89

What is the reporting currency for Sanofi?

Sanofi reports financial results in EUR

What is the latest annual turnover for Sanofi?

The latest annual turnover of Sanofi is EUR 46.11B

What is the latest annual profit for Sanofi?

The latest annual profit of Sanofi is EUR 5.56B

What is the registered address of Sanofi?

The registered address for Sanofi is 46, AVENUE DE LA GRANDE ARMEE, PARIS, PARIS, 75017

What is the Sanofi website address?

The website address for Sanofi is www.sanofi.com

Which industry sector does Sanofi operate in?

Sanofi operates in the PHARMACEUTICAL PREPARATIONS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
MPTImpianti SpA	0.99 € (21.47%)	568.5k
1LEVILevi Strauss & Co	17.68 € (15.44%)	6
WFCT26Fincantieri SpA	0.9201 € (14.30%)	2.03M
1AAGAumann AG	11.66 € (12.33%)	70
SESSesa SPA	77.95 € (10.88%)	130.3k
WSAC25Saccheria Flli Franceschetti SpA	0.01 € (-50.00%)	4k
WAMB26Ambromobiliare SpA	0.028 € (-29.82%)	36.9k
WPSQ26Pasquarelli Auto SpA	0.0071 € (-29.00%)	110k
AURNB Aurora SA SicafRaif	10.00 € (-26.50%)	7.9k
ELNElEn SpA	9.47 € (-15.22%)	881.82k
TITTelecom Italia SpA	0.2961 € (5.86%)	700.09M
TITRTelecom Italia	0.3291 € (4.24%)	81.11M
ISPIntesa Sanpaolo Spa	4.792 € (1.55%)	59.37M
SPMSaipem Spa	2.066 € (2.73%)	36.6M
ENELEnel Spa	7.016 € (0.30%)	33.93M

EZ2 4 분 전

MAGA. 💥

Viking61 4 분 전

FYI, delta is the difference in share price between Fannie and Freddie.

FNMA

Wayne R 4 분 전

They should add in their disclaimers 'all current and future shareholders are most likely to get screwed'

MULN

DaJester 4 분 전

try and score cheap points via name-calling and technicalities

Oh wow that's rich. Me calling you a hypocrite is "name-calling" but when you do it, it's "educating" people. LOL!! As I've said before, I am just using your tactics against you, so you know how it feels and maybe realize

FNMA

mr34 5 분 전

Shareholders meeting going on now , no live questions like an analyst would normally ask a ceo ….i will say this , revenue going to be a while ,so stop getting fomo from Sunny and his amateur friends

SDRC

NorCalTommy 5 분 전

I did notice that the Reverse SPAC merger seemed to work out nicely for USA Rare Earth', in their case they didn't get SPAC'led by the shareholders pulling out, they actually received the proceeeds from the SPAC ($50M+) during the process..... Maybe Mark should talk to US Rare Earth's CEO, Josh Ball

Cosa 5 분 전

I love the conviction from the longs here 👊

IOVA

stockwrestler2 5 분 전

ROK Resources owns just over 17% of EMP Metals, a holder of lithium properties in Saskatchewan.

janice shell 6 분 전

I take it you know Scott Bessent once worked for Soros. I'm guessing he failed to learn some important things.

dennisdave 6 분 전

so on top of NWBO investing tens of millions in Advent without Advent being an NWBO subsidiary but Linds's private CDMO without shareholders' consent, we all have to realize that in the not-to-far distant future NWBO will not be needing Advent because of Flaskworks.

All that time and

CDMO CRL NWBO

Aram1 6 분 전

Warrants will get canceled here soon!!! Shareholders will not get screwed twice. You can take that to the bank!

FNMA

DaJester 7 분 전

Yes, we have been through this before, but you are the one who has things wrong here.

Well you are entitled to your opinion, and I'm entitled to mine. The resolution will be coming so we will see who is more "wrong" - time will dissolve opinions into cold hard facts.

J

FNMA

hedge_fun 7 분 전

So we I say Soros is hiring, it’s a……

reference to his money.

I doubt he ever had direct contact with his hired hoodlums.

Not much of a grass roots movement if you gotta hire folks.

chemist72 7 분 전

Volume today 4.8M.
Highest volume since 6/6/2024 (6.6M).

GDVM

Bubae 7 분 전

Seriously Janet. You have been pumping this since the 52 week high. You haven't held all this time right? Are you in charge of the "Telvantis Ambassadors Group"? You have my vote. Dedication should not go unrewarded. :-D

RDAR

StayHumble 8 분 전

✅651Million+ Historic Xpert BUYS💹 $9.99 High Sell Orders✅ 💹 https://ih.advfn.com/stock-market/USOTC/medical-marijuana-pk-MJNA/historical?_gl=1*1yndril*_gcl_au*MTI1NDQyNTM1NS4xNzMxNjA2NTY3

MJNA

IanFromSI 8 분 전

Probably back to SI.

They don’t prevent their users from reading post which are accurate and correct the errors that were previously posted.

NVDA

John_Vallay 8 분 전

CNTM stock price is sure to go down.

Yesterday they announced a stock buy back of $10 million. Absolutely misleading since they do not have $10 million. In fact, they are debt ridden so them making that announcement is wrong on so many levels. Not to mention they are losing money whic

CNTM

DiscoverGold 8 분 전

Natural Gas Tests Resistance Amid Weakening Decline
By: Bruce Powers | March 14, 2025

• Natural gas remains below key resistance levels, signaling continued weakness unless it reclaims the 20-Day MA and trendline. A break below $3.93 shows weakness.

Natural

OILBRENT

Slojab 8 분 전

It just keeps getting sillier and sillier. Right Thomas?

K-9 bomb sniffer dog units have become the latest victims of the so-called Department of Government Efficiency, just as the White House celebrated a national day honoring the heroic animals.

Workers at the TSA wer

hbhmb 8 분 전

Oh I believe your driving record and your lack of compassion and soul.

Sad and pathetic

TSLA

Redoocs 9 분 전

And the rest of your investment will also disappear.
Sounds like you like losing money.
Buy high, post hatred of the company online, lose money.
Great investment strategy.

Oh yea, I'm still up, not much, but up.
And always will be.

DBMM

paulie c 9 분 전

Where the hell is Powerattles, Boywonder and all the other promoters...MORRISON QUIT!

KOAN

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Sanofi (1SAN)

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

Sanofi 정보

1SAN 최신 뉴스

Communiqué de presse : Présentation de dernière heure de données pivots positives sur le Dupixent dans le traitement de la pemphigoïde bulleuse à l’AAD

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Press release: Sanofi successfully prices EUR 1.5 billion of bond issue

Communiqué de presse : Sanofi place 1,5 milliard d’euros d’emprunts obligataires

Communiqué de presse : Sarclisa approuvé au Japon pour le traitement du myélome multiple nouvellement diagnostiqué

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

Communiqué de presse : ECCO 2025 : de nouvelles données sur le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn

Press Release: Sanofi and CD&R sign Opella share purchase agreement

Communiqué de presse : Sanofi et CD&R annoncent la signature de l’accord d’achat des actions d’Opella

Communiqué de presse : Présentation de dernière heure de données pivots positives sur le Dupixent dans le traitement de la pemphigoïde bulleuse à l’AAD

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Communiqué de presse : Sanofi place 1,5 milliard d’euros d’emprunts obligataires

Press release: Sanofi successfully prices EUR 1.5 billion of bond issue

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma

Communiqué de presse : Sarclisa approuvé au Japon pour le traitement du myélome multiple nouvellement diagnostiqué

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

Communiqué de presse : ECCO 2025 : de nouvelles données sur le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn

1SAN - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Sanofi (1SAN) 시세

Sanofi (1SAN)

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

Sanofi 정보

1SAN 최신 뉴스

Communiqué de presse : Présentation de dernière heure de données pivots positives sur le Dupixent dans le traitement de la pemphigoïde bulleuse à l’AAD

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Press release: Sanofi successfully prices EUR 1.5 billion of bond issue

Communiqué de presse : Sanofi place 1,5 milliard d’euros d’emprunts obligataires

Communiqué de presse : Sarclisa approuvé au Japon pour le traitement du myélome multiple nouvellement diagnostiqué

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

Communiqué de presse : ECCO 2025 : de nouvelles données sur le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn

Press Release: Sanofi and CD&R sign Opella share purchase agreement

Communiqué de presse : Sanofi et CD&R annoncent la signature de l’accord d’achat des actions d’Opella

Communiqué de presse : Présentation de dernière heure de données pivots positives sur le Dupixent dans le traitement de la pemphigoïde bulleuse à l’AAD

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Communiqué de presse : Sanofi place 1,5 milliard d’euros d’emprunts obligataires

Press release: Sanofi successfully prices EUR 1.5 billion of bond issue

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma

Communiqué de presse : Sarclisa approuvé au Japon pour le traitement du myélome multiple nouvellement diagnostiqué

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

Communiqué de presse : ECCO 2025 : de nouvelles données sur le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn

1SAN - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거